Upon its FDA approval in 2018, Teva’s migraine prevention medicine Ajovy faced tough prospects as it trailed a rival into the market with a less desirable delivery method. Nearly two years later, with ...
Ajovy now offers patients greater flexibility with two dosing options available in both an autoinjector and a prefilled syringe. Itis the first and only subcutaneous anti-CGRP treatment with both ...
TORONTO, Feb. 4, 2026 /CNW/ - Teva Canada Limited (Teva Canada) announced today that Health Canada has approved an expanded indication for Pr AJOVY® (fremanezumab solution for subcutaneous injection) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results